DE69834921D1 - Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält - Google Patents

Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält

Info

Publication number
DE69834921D1
DE69834921D1 DE69834921T DE69834921T DE69834921D1 DE 69834921 D1 DE69834921 D1 DE 69834921D1 DE 69834921 T DE69834921 T DE 69834921T DE 69834921 T DE69834921 T DE 69834921T DE 69834921 D1 DE69834921 D1 DE 69834921D1
Authority
DE
Germany
Prior art keywords
antigen
adjuvanties
derivated
monoglycerides
diglycerides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69834921T
Other languages
English (en)
Other versions
DE69834921T2 (de
Inventor
Sveinbjoern Gizurarson
Vera Gudmundsdottir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LYFJATHROUN H F ICELANDIC
Original Assignee
LYFJATHROUN H F ICELANDIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LYFJATHROUN H F ICELANDIC filed Critical LYFJATHROUN H F ICELANDIC
Application granted granted Critical
Publication of DE69834921D1 publication Critical patent/DE69834921D1/de
Publication of DE69834921T2 publication Critical patent/DE69834921T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cultivation Of Plants (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
DE69834921T 1997-07-09 1998-07-09 Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält Expired - Fee Related DE69834921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS451897 1997-07-09
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni
PCT/IS1998/000006 WO1999002186A2 (en) 1997-07-09 1998-07-09 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant

Publications (2)

Publication Number Publication Date
DE69834921D1 true DE69834921D1 (de) 2006-07-27
DE69834921T2 DE69834921T2 (de) 2007-01-18

Family

ID=36699745

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834921T Expired - Fee Related DE69834921T2 (de) 1997-07-09 1998-07-09 Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält

Country Status (13)

Country Link
US (2) US6514503B1 (de)
EP (1) EP1003551B1 (de)
JP (1) JP2001509491A (de)
KR (1) KR20010021622A (de)
CN (1) CN1202863C (de)
AT (1) ATE329617T1 (de)
AU (1) AU745849B2 (de)
BR (1) BR9810568A (de)
CA (1) CA2295237A1 (de)
DE (1) DE69834921T2 (de)
ES (1) ES2267189T3 (de)
IS (2) IS4518A (de)
WO (1) WO1999002186A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
AU755445B2 (en) * 1998-05-07 2002-12-12 Corixa Corporation Adjuvant composition and methods for its use
ATE516046T1 (de) 1999-05-13 2011-07-15 Wyeth Corp Adjuvans kombinationsformulierungen
WO2001012222A1 (en) * 1999-08-18 2001-02-22 Kim Ho Youn Immunological tolerance-induction agent
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
GB0007465D0 (en) 2000-03-29 2000-05-17 Amersham Pharm Biotech Uk Ltd Substrate for a lipase enzyme assay
BR0111834A (pt) * 2000-06-22 2003-07-08 American Cyanamid Co Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
WO2002038177A2 (en) * 2000-11-10 2002-05-16 Wyeth Holdings Corporation Adjuvant combination formulations
JP2005508143A (ja) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
DE60234695D1 (de) * 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
CA2457595A1 (en) * 2001-08-16 2003-02-27 Lyfjathroun H.F., Biopharmaceuticals A method of producing antibodies ex-vivo
CA2468845C (en) * 2001-12-03 2011-08-23 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
EP1476183A1 (de) * 2002-02-25 2004-11-17 Lyfjathroun HF, Biopharmaceutical Research Immunologisches adjuvans
NZ534738A (en) * 2002-02-25 2007-01-26 Lyfjathroun Hf Absorption enhancing agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
EP1566621A4 (de) * 2002-11-21 2010-04-07 Sapporo Immuno Diagnostic Lab Instrument zum sammeln und zur wiedergewinnung von speichel
BR0316685A (pt) * 2002-12-17 2005-11-01 Nastech Pharm Co Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US20050100621A1 (en) * 2003-11-07 2005-05-12 Popp Karl F. Dermatological compositions
US20060264505A1 (en) * 2003-11-07 2006-11-23 Stiefel Laboratories, Inc. Dermatological compositions
CN102861325A (zh) * 2003-11-10 2013-01-09 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
US20090130127A1 (en) 2005-08-01 2009-05-21 Seiji Tokumoto Adjuvant or Pharmaceutical Preparation for Transdermal or Transmucousal Administration
WO2008022298A2 (en) * 2006-08-17 2008-02-21 The Uab Research Foundation Immunogenic pcpa polypeptides and uses thereof
US20100047327A1 (en) * 2007-01-31 2010-02-25 Tetsuji Kuwahara Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
CA2688009C (en) 2007-05-23 2019-04-02 David E. Briles Detoxified pneumococcal neuraminidase and uses thereof
JP2012505197A (ja) * 2008-10-08 2012-03-01 イミューン・ソリューションズ・リミテッド 粘膜免疫を生成するための経口ワクチン
RU2543281C2 (ru) * 2009-03-11 2015-02-27 Акцо Нобель Н.В. Состав гербицида, содержащий глифосат и алкоксилированные глицериды (варианты) и способ борьбы с нежелательной растительностью
AU2010232180B2 (en) * 2009-03-31 2016-09-22 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2015064710A1 (ja) 2013-10-31 2015-05-07 久光製薬株式会社 アジュバント組成物、これを含むアジュバント製剤、及びキット
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE545978A (de) 1955-03-11
FR2253499B1 (de) 1973-12-10 1977-11-04 Fabre Sa Pierre
US4420484A (en) 1979-08-13 1983-12-13 Sterling Drug Inc. Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use therof
DE3225706C2 (de) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
JPS60149510A (ja) * 1984-01-13 1985-08-07 Kao Corp 農薬組成物
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4771571A (en) 1986-12-31 1988-09-20 Nabisco Brands, Inc. Method for treating pineapple to prevent pineapple fruit diseases
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
EP0324455A3 (de) * 1988-01-15 1991-03-27 Hans O. Ribi Neue polymerische Immuno-Adjuvans
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5177091A (en) * 1990-12-06 1993-01-05 Ciba-Geigy Corporation Use of carbazones as novel active ingredients in medicaments
CA2106079C (en) * 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
ES2136620T3 (es) * 1991-04-19 1999-12-01 Lds Technologies Inc Formulaciones de microemulsiones convertibles.
CA2083553A1 (en) 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
GB9207799D0 (en) 1992-04-09 1992-05-27 Procter & Gamble Aqueous compositions
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
CA2147272C (en) 1992-10-16 1999-12-21 Albert J. Owen Convertible microemulsion formulations
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
AU6018894A (en) 1993-01-15 1994-08-15 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US6013277A (en) * 1994-08-05 2000-01-11 Inpharma S.A. Compositions for topical treatment of erectile impotence
FR2729307B1 (fr) * 1995-01-18 1997-04-18 Seppic Sa Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain
US5744137A (en) 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
EP0833621B1 (de) * 1995-06-09 2002-01-30 R.P. Scherer Technologies, Inc. Weichgelatinekapsel mit teilchenmaterial
TW410158B (en) 1995-11-30 2000-11-01 Chemo Sero Therapeut Res Inst Oil adjuvant vaccine and method for preparing same
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
ID18079A (id) * 1996-08-26 1998-02-26 Takeda Chemical Industries Ltd Komposisi farmasi yang mengandung bahan pemercepat osteogenesis
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
FR2773489B1 (fr) * 1998-01-15 2001-03-23 Immunotech Sa Nouvelle composition destinee a la voie oromuqueuse notamment pernasale
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1034792A1 (de) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasale Verabreichung von Pneumokokken-Polysaccharid Impfstoffen
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent

Also Published As

Publication number Publication date
CN1262626A (zh) 2000-08-09
WO1999002186A3 (en) 1999-04-01
US6514503B1 (en) 2003-02-04
IS5329A (is) 1999-12-29
JP2001509491A (ja) 2001-07-24
EP1003551A2 (de) 2000-05-31
BR9810568A (pt) 2000-09-19
US20030099659A1 (en) 2003-05-29
CA2295237A1 (en) 1999-01-21
IS4518A (is) 1999-01-10
ATE329617T1 (de) 2006-07-15
EP1003551B1 (de) 2006-06-14
DE69834921T2 (de) 2007-01-18
KR20010021622A (ko) 2001-03-15
WO1999002186A2 (en) 1999-01-21
AU8459898A (en) 1999-02-08
ES2267189T3 (es) 2007-03-01
AU745849B2 (en) 2002-04-11
CN1202863C (zh) 2005-05-25

Similar Documents

Publication Publication Date Title
DE69834921D1 (de) Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
HK1046016A1 (en) Recombinant gelatin in vaccines
BR9406652A (pt) Composição
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
DE69511379T2 (de) Immunogens gegen gonadotropin releasing hormone
JPS546787A (en) Luminous element
ATE116993T1 (de) Saponin-hilfsmittel.
GB9808327D0 (en) Antidiotypic compounds
GB9626484D0 (en) Helicobacter pylori antigenic protein preparation and immunoassays
MXPA01009316A (es) Metodo para exrpesar una molecula antigenica, o una parte de la misma, sobre la superficie de una celula por incorporacion fotoquimica.
EA199900069A1 (ru) Вакцинная композиция против малярии
DE69726712D1 (de) Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
DE3877594D1 (de) Gaserzeugende zusammensetzung.
DE69940774D1 (de) Hla-bindende peptide und ihre verwendungen
FI911973A0 (fi) Traodaktigt hemagglutinin av b. pertussis-bacill.
WO2004058188A3 (en) Vaccine compositions and methods
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
NO154969C (no) Fremgangsmaate for fremstilling av brensel, saerlig til bruk i hvirvelbrennere, samt anvendelse av samme.
DE69840438D1 (en) Antigen
DK0589348T4 (da) Fremgangsmåde til immunkemisk kvantificering af inaktiverede antigener
AR012896A1 (es) Polipeptido flge de helicobacter pylori, composicion de vacuna, uso de dicho polipeptido para la fabricacion de composiciones, metodo de diagnostico invitro, y kit de diagnostico para la deteccion de la infeccion por helicobacter pylori
IT7925043A0 (it) Elemento prefabbricato tridimensionale per edilizia, fungente anche da rivestimento per mobili e simili.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee